CLC bio has implemented specialized antibody engineering and selection software for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio's bioinformatics platform.
The specialized module will optimize workflow and analysis pipeline when working with a huge number of antibodies during the development of new therapies including infectious diseases and cancer.
Crucell innovation and discovery scientist David Zuijdgeest said CLC bio has fully integrated the workflow by automating all the steps in the downstream bioinformatics analysis process.
"Not only has this accelerated the research process tremendously by eliminating tedious and complicated manual procedures, but it also provides a high quality and robust workflow," Zuijdgeest added.
CLC bio consulting services director Jannick Bendtsen said, "This intricate solution which we have customized for Crucell stresses the flexibility and stability of our bioinformatics platform."